- Home
- CRGX vs NXDT Comparison
CRGX vs NXDT Comparison
Compare CRGX & NXDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- NXDT
- Stock Information
- Founded
- CRGX 2021
- NXDT 2012
- Country
- CRGX United States
- NXDT United States
- Employees
- CRGX N/A
- NXDT N/A
- Industry
- CRGX
- NXDT Investment Managers
- Sector
- CRGX
- NXDT Finance
- Exchange
- CRGX Nasdaq
- NXDT Nasdaq
- Market Cap
- CRGX 213.5M
- NXDT 192.3M
- IPO Year
- CRGX 2023
- NXDT N/A
- Fundamental
- Price
- CRGX $4.52
- NXDT $4.87
- Analyst Decision
- CRGX Hold
- NXDT
- Analyst Count
- CRGX 7
- NXDT 0
- Target Price
- CRGX $5.33
- NXDT N/A
- AVG Volume (30 Days)
- CRGX 3.0M
- NXDT 133.6K
- Earning Date
- CRGX 08-11-2025
- NXDT 01-01-0001
- Dividend Yield
- CRGX N/A
- NXDT 9.66%
- EPS Growth
- CRGX N/A
- NXDT N/A
- EPS
- CRGX N/A
- NXDT 0.99
- Revenue
- CRGX N/A
- NXDT N/A
- Revenue This Year
- CRGX $57.81
- NXDT N/A
- Revenue Next Year
- CRGX N/A
- NXDT N/A
- P/E Ratio
- CRGX N/A
- NXDT $6.41
- Revenue Growth
- CRGX N/A
- NXDT N/A
- 52 Week Low
- CRGX $3.00
- NXDT $5.89
- 52 Week High
- CRGX $25.45
- NXDT $13.07
- Technical
- Relative Strength Index (RSI)
- CRGX 54.72
- NXDT 57.33
- Support Level
- CRGX $4.40
- NXDT $4.78
- Resistance Level
- CRGX $4.63
- NXDT $5.26
- Average True Range (ATR)
- CRGX 0.07
- NXDT 0.30
- MACD
- CRGX -0.01
- NXDT 0.00
- Stochastic Oscillator
- CRGX 34.29
- NXDT 54.65
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.